ALK and non-small cell lung carcinoma: Therefore, in this systematic review and NMA (registration: UMIN-CTR no. UMIN000043994), we compared and ranked the efficacy and safety of six treatment groups, including lorlatinib, brigatinib, alectinib, ceritinib, crizotinib, and platinum-based chemotherapy, in patients with ALK-p advanced NSCLC, using the Bayesian NMA statistical method [37,40,41].